Cargando…

Purified anti-CD3 × anti-HER2 bispecific antibody potentiates cytokine-induced killer cells of poor spontaneous cytotoxicity against breast cancer cells

BACKGROUND: Chemical crosslinking is the most straightforward method to produce bispecific antibodies (BsAb) for arming ex vivo activated cytotoxic T lymphocytes. However, heterogeneous polymers are produced by chemical crosslinking. Currently, it is not known under what circumstances or to what ext...

Descripción completa

Detalles Bibliográficos
Autores principales:	He, Qingzhong, Zhang, Haisong, Wang, Youzhao, Ting, Hong Hoi, Yu, Wenhua, Cao, Xuetao, Ge, Wei
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2014
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4258008/ https://www.ncbi.nlm.nih.gov/pubmed/25485089 http://dx.doi.org/10.1186/2045-3701-4-70

Ejemplares similares

Cytotoxicity of cytokine-induced killer cells targeted by a bispecific antibody to gastric cancer cells
por: ZHANG, LIN, et al.
Publicado: (2013)

A novel asymmetrical anti-HER2/CD3 bispecific antibody exhibits potent cytotoxicity for HER2-positive tumor cells
por: Yu, Shengnan, et al.
Publicado: (2019)

Costimulatory T cell engagement via a novel bispecific anti-CD137 /anti-HER2 protein
por: Hinner, Marlon J, et al.
Publicado: (2015)

A vector-encoded bispecific killer engager to harness virus-activated NK cells as anti-tumor effectors
por: Floerchinger, Alessia, et al.
Publicado: (2023)

Development and clinical application of anti-HER2 monoclonal and bispecific antibodies for cancer treatment
por: Yu, Shengnan, et al.
Publicado: (2017)

Structural and functional characterization of MBS301, an afucosylated bispecific anti-HER2 antibody
por: Huang, Sijia, et al.
Publicado: (2018)

Development of humanized bispecific antibodies reactive with cytotoxic lymphocytes and tumor cells overexpressing the HER2 protooncogene
Publicado: (1992)

In vitro induction of cytotoxic effector cells with spontaneous killer cell specificity
Publicado: (1978)

Effect of anti-asthma Chinese medicine Chuankezhi on the anti-tumor activity of cytokine-induced killer cells
por: Zhao, Jing-Jing, et al.
Publicado: (2013)

A Human Anti-M2 Antibody Mediates Antibody-Dependent Cell-Mediated Cytotoxicity (ADCC) and Cytokine Secretion by Resting and Cytokine-Preactivated Natural Killer (NK) Cells
por: Simhadri, Venkateswara R., et al.
Publicado: (2015)

The Fyn–ADAP Axis: Cytotoxicity Versus Cytokine Production in Killer Cells
por: Gerbec, Zachary J., et al.
Publicado: (2015)

A Novel Anti-HER2 Bispecific Antibody With Potent Tumor Inhibitory Effects In Vitro and In Vivo
por: Mohammadi, Mehdi, et al.
Publicado: (2021)

T-Bet Mediated Anti-Neoplastic Effects of Dendritic Cell-Cytokine Induced Killer Cells in vitro
por: Miao, Liu, et al.
Publicado: (2012)

Phase II clinical trial using anti-CD3 × anti-HER2 bispecific antibody armed activated T cells (HER2 BATs) consolidation therapy for HER2 negative (0–2+) metastatic breast cancer
por: Lum, Lawrence G., et al.
Publicado: (2021)

Interplay between Natural Killer Cells and Anti-HER2 Antibodies: Perspectives for Breast Cancer Immunotherapy
por: Muntasell, Aura, et al.
Publicado: (2017)

The role of apoptosis in bispecific antibody-mediated T-cell cytotoxicity.
por: Kroesen, B. J., et al.
Publicado: (1996)

Bp-Bs, a Novel T-cell Engaging Bispecific Antibody with Biparatopic Her2 Binding, Has Potent Anti-tumor Activities
por: Liu, Jiayu, et al.
Publicado: (2019)

BiHC, a T-Cell–Engaging Bispecific Recombinant Antibody, Has Potent Cytotoxic Activity Against Her2 Tumor Cells()
por: Xing, Jieyu, et al.
Publicado: (2017)

Sunitinib Indirectly Enhanced Anti-Tumor Cytotoxicity of Cytokine-Induced Killer Cells and CD3(+)CD56(+) Subset through the Co-Culturing Dendritic Cells
por: Wongkajornsilp, Adisak, et al.
Publicado: (2013)

HER2/PD1 bispecific antibody in IgG4 subclass with superior anti‐tumour activities
por: Chu, Wendi, et al.
Publicado: (2022)

Antitumor Activity of an Anti-EGFR/HER2 Bispecific Antibody in a Mouse Xenograft Model of Canine Osteosarcoma
por: Tateyama, Nami, et al.
Publicado: (2022)

Phase I Study of Anti-CD3 x Anti-Her2 Bispecific Antibody in Metastatic Castrate Resistant Prostate Cancer Patients
por: Vaishampayan, Ulka, et al.
Publicado: (2015)

A single-domain antibody-linked Fab bispecific antibody Her2-S-Fab has potent cytotoxicity against Her2-expressing tumor cells
por: Li, Aifen, et al.
Publicado: (2016)

Bispecific antibodies enhance tumor‐infiltrating T cell cytotoxicity against autologous HER‐2‐expressing high‐grade ovarian tumors
por: Oberg, Hans‐Heinrich, et al.
Publicado: (2019)

Src/lck inhibitor dasatinib reversibly switches off cytokine release and T cell cytotoxicity following stimulation with T cell bispecific antibodies
por: Leclercq, Gabrielle, et al.
Publicado: (2021)

Bispecific antibodies (anti-mPEG/anti-HER2) for active tumor targeting of docetaxel (DTX)-loaded mPEGylated nanocarriers to enhance the chemotherapeutic efficacy of HER2-overexpressing tumors
por: Su, Chia-Yu, et al.
Publicado: (2018)

Targeting B7-H3 via chimeric antigen receptor T cells and bispecific killer cell engagers augments antitumor response of cytotoxic lymphocytes
por: Liu, Jie, et al.
Publicado: (2021)

Cytotoxic Function and Cytokine Production of Natural Killer Cells and Natural Killer T-Like Cells in Systemic Lupus Erythematosis Regulation with Interleukin-15
por: Lin, Syh-Jae, et al.
Publicado: (2019)

Cryopreserved anti-CD22 and bispecific anti-CD19/22 CAR T cells are as effective as freshly infused cells
por: Dreyzin, Alexandra, et al.
Publicado: (2022)

Comparison of the proliferation, cytotoxic activity and cytokine secretion function of cascade primed immune cells and cytokine-induced killer cells in vitro
por: LI, GUI-XIN, et al.
Publicado: (2015)

A Combination of Cytokines Rescues Highly Purified Leukemic CLL B-Cells from Spontaneous Apoptosis In Vitro
por: Ghamlouch, Hussein, et al.
Publicado: (2013)

Bispecific Antibody‐directed Antitumor Activity of Human CD4(+) Helper/Killer T Cells Induced by Anti–CD3 Monoclonal Antibody plus Interleukin 2
por: Nishimura, Takashi, et al.
Publicado: (1991)

Fc-comprising scDb-based trivalent, bispecific T-cell engagers for selective killing of HER3-expressing cancer cells independent of cytokine release
por: Aschmoneit, Nadine, et al.
Publicado: (2021)

“Anomalous” THY-1(+) killer cells in allogeneic and F1-anti-parental mixed leukocyte culture. Relation to natural killer cells and allospecific cytotoxic T lymphocytes
por: Karre, K, et al.
Publicado: (1982)

"Anomalous" Thy-1+ killer cells in allogeneic and F1-anti-parental mixed leukocyte culture. Relation to natural killer cells and allospecific cytotoxic T lymphocytes
Publicado: (1983)

In vitro analysis of the proliferative capacity and cytotoxic effects of ex vivo induced natural killer cells, cytokine-induced killer cells, and gamma-delta T cells
por: Niu, Chao, et al.
Publicado: (2015)

Functional Domain Order of an Anti-EGFR × Anti-CD16 Bispecific Diabody Involving NK Cell Activation
por: Kuwahara, Atsushi, et al.
Publicado: (2020)

An anti-HER2 biparatopic antibody that induces unique HER2 clustering and complement-dependent cytotoxicity
por: Weisser, Nina E., et al.
Publicado: (2023)

Monoclonal and Bispecific Anti-BCMA Antibodies in Multiple Myeloma
por: Dalla Palma, Benedetta, et al.
Publicado: (2020)

Cytokine-induced killer cells/natural killer cells combined with anti-GD2 monoclonal antibody increase cell death rate in neuroblastoma SK-N-SH cells
por: Zhang, Chi, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_6jpnbqffue1vgkf6p0mnhoisth